2l6t
From Proteopedia
(Difference between revisions)
| (12 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Efficacy of an HIV-1 entry inhibitor targeting the GP41 fusion peptide== | |
| - | + | <StructureSection load='2l6t' size='340' side='right'caption='[[2l6t]]' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[2l6t]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2L6T OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2L6T FirstGlance]. <br> | |
| - | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR</td></tr> | |
| - | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2l6t FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2l6t OCA], [https://pdbe.org/2l6t PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2l6t RCSB], [https://www.ebi.ac.uk/pdbsum/2l6t PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2l6t ProSAT]</span></td></tr> | |
| - | + | </table> | |
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Adermann K]] | ||
| + | [[Category: Albrecht U]] | ||
| + | [[Category: Barlos K]] | ||
| + | [[Category: Busmann A]] | ||
| + | [[Category: Can les-Mayordomo A]] | ||
| + | [[Category: Forssmann W]] | ||
| + | [[Category: Gimenez-Gallego G]] | ||
| + | [[Category: Hirsch J]] | ||
| + | [[Category: Jimenez-Barbero J]] | ||
| + | [[Category: Kirchhoff F]] | ||
| + | [[Category: Meyer-Olson D]] | ||
| + | [[Category: Muench J]] | ||
| + | [[Category: Perez-Castells J]] | ||
| + | [[Category: Schmidt RE]] | ||
| + | [[Category: Staendker L]] | ||
| + | [[Category: Stoll M]] | ||
| + | [[Category: The Y]] | ||
Current revision
Efficacy of an HIV-1 entry inhibitor targeting the GP41 fusion peptide
| |||||||||||
